JP2019519615A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519615A5 JP2019519615A5 JP2019520488A JP2019520488A JP2019519615A5 JP 2019519615 A5 JP2019519615 A5 JP 2019519615A5 JP 2019520488 A JP2019520488 A JP 2019520488A JP 2019520488 A JP2019520488 A JP 2019520488A JP 2019519615 A5 JP2019519615 A5 JP 2019519615A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- treatment
- composition according
- prevention
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 6
- 238000011282 treatment Methods 0.000 claims 6
- 230000002265 prevention Effects 0.000 claims 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- -1 said groups Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305769.8 | 2016-06-24 | ||
| EP16305769.8A EP3260452A1 (en) | 2016-06-24 | 2016-06-24 | Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-ht1a receptors |
| PCT/EP2017/065585 WO2017220799A1 (en) | 2016-06-24 | 2017-06-23 | Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-ht1a receptors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519615A JP2019519615A (ja) | 2019-07-11 |
| JP2019519615A5 true JP2019519615A5 (enExample) | 2020-07-30 |
| JP6935873B2 JP6935873B2 (ja) | 2021-09-15 |
Family
ID=56404042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520488A Active JP6935873B2 (ja) | 2016-06-24 | 2017-06-23 | ５−ｈｔ１ａ受容体によってコントロールされるセロトニン作動性制御に対する感受性が高い障害を処置するための新規化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10562853B2 (enExample) |
| EP (2) | EP3260452A1 (enExample) |
| JP (1) | JP6935873B2 (enExample) |
| CN (1) | CN109563073B (enExample) |
| AU (1) | AU2017281742B2 (enExample) |
| CA (1) | CA3028036A1 (enExample) |
| DK (1) | DK3475268T3 (enExample) |
| ES (1) | ES2831853T3 (enExample) |
| WO (1) | WO2017220799A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119874616B (zh) * | 2025-03-28 | 2025-05-30 | 四川美域高生物医药科技有限公司 | 一种有机中间体及其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2702211B1 (fr) * | 1993-03-04 | 1995-06-02 | Pf Medicament | Nouveaux dérivés de la phénoxy-2 éthylamine, leur préparation et leur application en thérapeutique. |
| FR2755967B1 (fr) | 1996-11-21 | 1999-01-29 | Pf Medicament | Derives de la pyridin-2-yl-methylamine, leur procede de preparation et leur application comme medicaments |
| FR2784378B1 (fr) * | 1998-10-09 | 2000-12-29 | Pf Medicament | Nouveaux derives d'aryl-(4-fluoro-4-[(2-pyridin-2-yl- ethylamino)-methyl]-piperidin-1-yl)-methanone, leur procede de preparation et leur utilisation a titre de medicaments |
| EP2058306A1 (en) * | 2007-11-08 | 2009-05-13 | Schwarz Pharma Ag | Heteroaryl-substituted 2-pyridinyl-methylamine derivatives |
| PL395470A1 (pl) * | 2011-06-29 | 2013-01-07 | Adamed Spólka Z Ograniczona Odpowiedzialnoscia | Sulfonamidowe pochodne amin alicyklicznych do leczenia chorób osrodkowego ukladu nerwowego |
-
2016
- 2016-06-24 EP EP16305769.8A patent/EP3260452A1/en not_active Withdrawn
-
2017
- 2017-06-23 CN CN201780038390.3A patent/CN109563073B/zh active Active
- 2017-06-23 WO PCT/EP2017/065585 patent/WO2017220799A1/en not_active Ceased
- 2017-06-23 DK DK17734043.7T patent/DK3475268T3/da active
- 2017-06-23 JP JP2019520488A patent/JP6935873B2/ja active Active
- 2017-06-23 EP EP17734043.7A patent/EP3475268B9/en active Active
- 2017-06-23 ES ES17734043T patent/ES2831853T3/es active Active
- 2017-06-23 CA CA3028036A patent/CA3028036A1/en active Pending
- 2017-06-23 US US16/312,847 patent/US10562853B2/en active Active
- 2017-06-23 AU AU2017281742A patent/AU2017281742B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014506907A5 (enExample) | ||
| JP2015537020A5 (enExample) | ||
| JP2016515561A5 (enExample) | ||
| JP2015509535A5 (enExample) | ||
| JP2019519598A5 (enExample) | ||
| JP2012144574A5 (enExample) | ||
| JP2017537940A5 (enExample) | ||
| AR088195A1 (es) | Composiciones farmaceuticas de n-metil-2-[3-(e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]-benzamida | |
| JP2014507455A5 (enExample) | ||
| JP2013032389A5 (enExample) | ||
| EA201201031A1 (ru) | Ингибиторы вируса гепатита с | |
| JP2013518107A5 (enExample) | ||
| WO2012018534A3 (en) | Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases | |
| JP2013542261A5 (enExample) | ||
| JP2014500861A5 (enExample) | ||
| WO2015081133A3 (en) | Nucleotides for the treatment of liver cancer | |
| JP2016518437A5 (enExample) | ||
| JP2013545785A5 (enExample) | ||
| CN103717571B8 (zh) | 9‑氨基甲基取代的四环素类化合物 | |
| JP2016540742A5 (enExample) | ||
| JP2017514910A5 (enExample) | ||
| JP2011527299A5 (enExample) | ||
| WO2013059278A3 (en) | Hepatitis c virus inhibitors | |
| JP2017531619A5 (enExample) | ||
| JP2019507111A5 (enExample) |